Fox Chase Cancer Center News

PHILADELPHIA (June 9, 2021)—A 70-year-old woman with Hodgkin Lymphoma being treated at Fox Chase Cancer Center had increased FDG uptake in her lymph nodes two days after receiving a COVID-19 vaccination. FDG is short for fluorodeoxyglucose, a radiolabeled sugar used during positron emission tomography (PET) scans.

PHILADELPHIA (June 9, 2021)—There’s growing evidence that statins can offer an effective treatment for medulloblastoma, a childhood brain cancer, without the severe side effects of other chemotherapy drugs. Now a new study by researchers at Fox Chase Cancer Center explains why.

PHILADELPHIA (June 9, 2021)—Researchers at Fox Chase Cancer Center investigating psychological distress in patients with metastatic cancer enrolling in phase 1 clinical trials found that although physical stressors did not strongly relate to patients’ overall level of distress, emotional, family, and practical stressors did.

PHILADELPHIA (June 8, 2021)—Researchers at Fox Chase Cancer Center have developed a model that predicts disease recurrence and survival in patients with kidney cancer more accurately than other models currently in use.

PHILADELPHIA (June 4, 2021) – A large retrospective study of real-world patients with renal cell carcinoma (RCC) showed similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they are treated with the combination of axitinib plus pembrolizumab or ipilimumab plus nivolumab.

PHILADELPHIA (June 4, 2021)—The likelihood of prostate cancer surgery for patients presenting for treatment across Pennsylvania declined among Black patients, but not white patients, during the initial wave of the COVID-19 pandemic, according to new research from Fox Chase Cancer Center.

PHILADELPHIA (June 3, 2021)—Researchers from Fox Chase Cancer Center have presented new data showing that oncologists feel underprepared to communicate the results of tumor genetic profiling (TGP) to their patients, particularly to African American patients who have more mistrust around healthcare and particularly around genetic information and testing.

PHILADELPHIA (June 3, 2021) – In a presentation of real-world data, researchers from Fox Chase Cancer Center have concluded that the choice of first-line platinum chemotherapy did not result in a significant difference in overall survival benefit among patients with advanced bladder cancer who were able to go on to receive second-line immunotherapy.